$4 million partnership to reduce barriers to the development of personalized medicine in oncology

At an announcement made earlier today, Merck confirmed its commitment to research and innovation in oncology by contributing a total of $2 million to the Exactis Innovation ‘Personalize My Treatment’ (PMT) initiative.

In addition, the Cancer Research Society (CRS) and the New Brunswick Health Research Foundation (NBHRF) will also contribute $1 million each to help bring innovative precision medicine to Canadians living with cancer.